Abstract: VBIT-4 is a novel, small-molecule inhibitor designed to target the voltage-dependent anion channel 1 (VDAC1), a critical mitochondrial protein involved in cellular energy regulation and apoptosis. Developed through high-throughput screening and subsequent medicinal chemistry optimization, VBIT-4 directly interacts with VDAC1 to prevent its oligomerization. By inhibiting this oligomerization, VBIT-4 effectively blocks the release of apoptogenic factors such as cytochrome c, prevents the detachment of mitochondrion-bound hexokinase, and protects against mitochondrial dysfunction, including membrane depolarization, reactive oxygen species (ROS) production, and intracellular calcium elevation. VBIT-4 demonstrates significant anti-apoptotic activity across multiple cell lines and exhibits a favorable safety profile in vivo. This compound represents a promising therapeutic candidate for diseases characterized by excessive apoptosis and mitochondrial dysfunction, including neurodegenerative and cardiovascular disorders.
1. Introduction
Mitochondria play a crucial role in cellular energy generation, metabolism, calcium homeostasis, and cell death. Located at the outer mitochondrial membrane (OMM), the voltage-dependent anion channel 1 (VDAC1) serves as a primary mitochondrial gatekeeper, mediating the flux of ions, nucleotides, and metabolites between the mitochondria and the cytosol [1]. Beyond its metabolic functions, VDAC1 is a convergence point for various cell survival and death signals and is a key player in mitochondrion-mediated apoptosis. During apoptosis, VDAC1 undergoes oligomerization to form a large, flexible pore that allows the release of pro-apoptotic proteins, such as cytochrome c (Cyto c) and apoptosis-inducing factor (AIF), from the intermembrane space into the cytosol, ultimately leading to caspase activation and cell death [1].
Because VDAC1 oligomerization is an early and critical step in the apoptotic cascade, it represents a prime pharmacological target for modulating cell death. While many existing apoptosis inhibitors target downstream events like caspase activity, there has been a significant need for agents that block apoptosis at its inception. Through high-throughput bioluminescence resonance energy transfer (BRET2)-based screening of a library of 1,468 drug-like compounds, followed by structure-activity relationship (SAR) optimization, VBIT-4 was developed as a highly specific and potent inhibitor of VDAC1 oligomerization [1].
2. Pharmacological Activity
VBIT-4 exhibits robust pharmacological activity by inhibiting apoptosis induced by a variety of pathological stimuli. In experimental models, VBIT-4 successfully prevented apoptosis induced by agents such as selenite, cisplatin, and staurosporine (STS) across multiple cell lines, including HEK-293, HeLa, and the neuroblastoma cell line SH-SY5Y [1]. The compound is highly potent, demonstrating half-maximal inhibitory concentration (IC50) values in the range of 1.8 to 2.9 μM for the inhibition of VDAC1 oligomerization, Cyto c release, and overall apoptosis [1]. Furthermore, VBIT-4's anti-apoptotic efficacy is maintained even in Bax/Bak-lacking mouse embryonic fibroblasts (MEFs), indicating that its protective effects are VDAC1-dependent rather than reliant on Bax/Bak pathways [1].
In addition to preventing cell death, VBIT-4 protects against apoptosis-associated mitochondrial dysfunction. It prevents the dissipation of the mitochondrial membrane potential (ΔΨm), halts the elevation of intracellular free calcium ([Ca2+]i), and completely suppresses the production of both cellular and mitochondrial reactive oxidative species (ROS) [1]. Importantly, VBIT-4 shows an excellent safety profile; it has no adverse effects on normal cell growth and viability. In vivo studies demonstrated that mice exposed to VBIT-4 for four months exhibited no signs of toxicity, as reflected by normal weight, behavior, and organ histochemistry [1].
3. Molecular Mechanism of Action
The primary molecular mechanism of VBIT-4 involves direct interaction with VDAC1, which shifts the protein's dynamic equilibrium from an oligomeric state back to a monomeric state. By directly binding to VDAC1, VBIT-4 reduces the channel's conductance and physically interferes with the protein-protein interactions required for VDAC1 monomers to assemble into the large oligomeric pores responsible for Cyto c release [1].
A secondary, yet highly critical, mechanism of action is VBIT-4's ability to prevent the detachment of hexokinase (HK) from the mitochondria. Under normal conditions, mitochondrion-bound HK (HK-I and HK-II) couples cytosolic glycolysis to mitochondrial oxidative phosphorylation and prevents the release of pro-apoptotic factors. Apoptotic triggers typically induce the dissociation of the VDAC1-HK complex, a prerequisite for apoptosis. VBIT-4 strongly inhibits this selenite-induced HK detachment, maintaining the protective VDAC1-HK complex and further solidifying its anti-apoptotic effect [1].
4. Structure-Activity Relationship (SAR)
VBIT-4 was synthesized as an optimized derivative of a parent hit compound, AKOS-022. During the medicinal chemistry optimization process, two main derivatives were created: VBIT-3 and VBIT-4. Both molecules featured the conjugation of a piperazine ring with an aniline moiety. However, VBIT-4 possesses a distinct structural advantage: the central part of the core was linearized to form a 4-hydroxybutanamide moiety, replacing the rigid pyrrolidine-2,5-dione ring found in VBIT-3 [1].
This specific structural modification makes VBIT-4 significantly more flexible (due to the linear moiety versus a cyclic group) and more hydrophilic (due to the presence of an alcohol group versus an amide). The increased flexibility is crucial for its ability to effectively interfere with the broad protein-protein interaction interfaces required for VDAC1 oligomerization. Consequently, VBIT-4 is more potent and effective than both VBIT-3 and AKOS-022. Additionally, VBIT-4 is a chiral molecule containing a chiral carbon. However, separation and testing of its two enantiomers (VBIT-4-1 and VBIT-4-2) revealed that both R and S conformations possess identical activity in inhibiting VDAC1 oligomerization and apoptosis, suggesting that the flexible molecule can access and bind the VDAC1 monomer interface regardless of its stereochemistry [1].
5. Current Limitations
While VBIT-4 is highly effective against a broad range of apoptotic inducers, it exhibits an anomalous response when apoptosis is induced by arsenic trioxide (As2O3). Instead of inhibiting cell death, the addition of VBIT-4 slightly enhanced As2O3-induced apoptosis [1]. The exact reason for this limitation remains unclear, but it is hypothesized that As2O3 possesses specific molecular targets and mechanisms—such as direct binding to promyelocytic leukemia (PML) proteins, interaction with sulfhydryl groups, or down-regulation of Bcl-2 expression—that are either unaffected or inadvertently exacerbated by the inhibition of VDAC1 oligomerization [1].
Furthermore, while VBIT-4 binds to native VDAC1 purified from rat liver mitochondria with high affinity, its binding affinity to recombinant VDAC isoforms (VDAC1, VDAC2, and VDAC3) is approximately threefold lower (affinity of 53 ± 3 μM). This discrepancy is likely due to the unfolding and refolding processes required for recombinant proteins, which may result in modified conformations that slightly hinder VBIT-4 binding [1].
6. Future Perspectives
The development of VBIT-4 opens significant therapeutic avenues for treating diseases characterized by excessive or inappropriate apoptosis. Because VDAC1 overexpression and subsequent oligomerization are implicated in various pathologies, VBIT-4 serves as a promising drug candidate for neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and schizophrenia, where HK detachment and neuronal apoptosis are prevalent [1].
Additionally, VBIT-4 holds potential for cardiovascular diseases. Conditions such as heart failure, myocardial infarction, cardiac ischemia/reperfusion injury, and atrial fibrillation are heavily linked to the activation of the mitochondrial apoptotic pathway and the loss of cardiomyocytes. By preventing VDAC1 oligomerization and preserving mitochondrial integrity, VBIT-4 could be utilized to inhibit pathological apoptosis in cardiac tissue [1]. Beyond its clinical potential, VBIT-4 provides a valuable pharmacological tool for researchers to further elucidate the complex roles of VDAC1 in cellular metabolism, energy production, and cholesterol transport [1].
